Afya Limited (AFYA) Q3 2025 Earnings Call Transcript

Afya Limited ( AFYA ) Q3 2025 Earnings Call November 12, 2025 5:00 PM EST Company Participants Renata Couto - Investor Relations Executive Manager Virgilio Deloy Gibbon - Chief Executive Officer Luis Andre Blanco - Chief Financial Officer Conference Call Participants Lucca Marquezini - Itaú Corretora de Valores S.A., Research Division Lucas Nagano - Morgan Stanley, Research Division Marcelo Santos - JPMorgan Chase & Co, Research Division Mirela Rodrigues de Oliveira - BofA Securities, Research Division Renan Prata - Citigroup Inc. Exchange Research Presentation Renata Couto Investor Relations Executive Manager Thank you for joining us for Afya's conference call.

Seeking Alpha • Nov 13, 2025

Afya Limited Announces Third Quarter and Nine Months 2025 Financial Results

BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and nine-month period, which ended September 30, 2025 (third quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Third Quarter 2025 High.

Business Wire • Nov 12, 2025

Afya (AFYA) Q3 Earnings Beat Estimates

Afya (AFYA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.32 per share a year ago.

Zacks Investment Research • Nov 13, 2025

Afya Limited Announces Medical Seats Increase in AFYA Faculdade de Ciências Médicas Bragança

BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, today announced that the Secretary of Regulation and Supervision of Higher Education of the Ministry of Education (“MEC”) authorized the increase of 100 medical seats of ITPAC Porto Nacional – Instituto Tocantinense Presidente Antonio Carlos Porto S.A. (AFYA Faculdade de Ciências Médicas Bragança), in t.

Business Wire • Nov 7, 2025

Afya Limited (AFYA) Analyst/Investor Day Transcript

Afya Limited (NASDAQ:AFYA ) Analyst/Investor Day October 22, 2025 8:00 AM EDT Company Participants Virgilio Deloy Gibbon - Chief Executive Officer Gustavo Meirelles Isabela Dupin Ronaldo Gismondi Luis Andre Blanco - Chief Financial Officer Renata Couto - Investor Relations Executive Manager Denis Del Bianco Erico Ribeiro Stella Brant Conference Call Participants Eduardo Moura Gustavo Meirelles Vinicius Figueiredo - Itaú Corretora de Valores S.A., Research Division Mirela Rodrigues de Oliveira - BofA Securities, Research Division Samuel Alves - Banco BTG Pactual S.A.

Seeking Alpha • Oct 24, 2025

Repurchase of the Series A Perpetual Convertible Preferred Shares and Repayment of Afya Participações S.A. Debentures

BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, announced today that it has entered into a Share Repurchase Agreement with SBLA Holdco LLC, an affiliate of Softbank, to repurchase all 150,000 Series A Perpetual Convertible Preferred Shares of a nominal or par value of US$0.00005 each in the capital of the Company (the "Series A Preferred Shares") for.

Business Wire • Oct 22, 2025

Issuance of Debentures

BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, announced today that its wholly owned subsidiary Afya Participações S.A. (“Afya Brazil”), has approved today the first issuance of book-entry commercial notes, in two series, for private placement, (the “Commercial Notes”), to be sold to Opea Securitizadora S.A. (“Opea”), a Brazilian securitization corp.

Business Wire • Oct 9, 2025

Afya's Multiple Is Back To Reasonable Levels, But Market Saturation Is Real

Afya's Q2 2025 results were solid, but the stock faces headwinds from market saturation and regulatory changes in Brazil's medical education sector. Valuation is now more attractive after a 20%+ price drop, but risks from lower pricing power, increased competition, and new quality exams remain significant. The company is shifting capital allocation toward buybacks and dividends, signaling fewer expansion opportunities and a focus on shareholder returns.

Seeking Alpha • Aug 16, 2025

Afya Limited (AFYA) Q2 2025 Earnings Call Transcript

Afya Limited (NASDAQ:AFYA ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Luis Andre Carpintero Blanco - Chief Financial Officer Virgilio Deloy Capobianco Gibbon - Chief Executive Officer Conference Call Participants Flavio Yoshida - BofA Securities, Research Division Lucca Generali Marquezini - Itaú Corretora de Valores S.A., Research Division Marcelo Peev dos Santos - JPMorgan Chase & Co, Research Division Mauricio I Cepeda - Morgan Stanley, Research Division Renan Prata - Citigroup Inc. Exchange Research Samuel Campos Alves - Banco BTG Pactual S.A.

Seeking Alpha • Aug 14, 2025

Afya Limited Announces Second-Quarter and First-Half 2025 Financial Results

BELO HORIZONTE, Brazil--(BUSINESS WIRE)--Afya Limited (Nasdaq: AFYA; B3: A2FY34) (“Afya” or the “Company”), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second-Quarter 2025 Highligh.

Business Wire • Aug 13, 2025